The antiviral remdesivir is superior to the standard of care for the treatment of Covid-19, NIH says, citing a report published today in The New England Journal of Medicine.
- “Ultimately, the findings support remdesivir as the standard therapy for patients hospitalized with Covid-19 and requiring supplemental oxygen therapy, according to the authors”
- The study began Feb. 21, 2020, and enrolled 1,063 participants in 10 countries in 58 days
- NOTE: Gilead Sciences’s remdesivir has been shown to benefit coronavirus patients in a clinical trial
To contact the reporter on this story:
To contact the editors...